Peerview Family Medicine & General Practice Cme/cne/cpe Audio Podcast

Go online to PeerView.com/QSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in Rett syndrome discusses the diagnosis and management of this rare disease, as well as the latest data on emerging treatment options. A 3D animation offers an overview of MECP2 mutation, hypothesized to be a major contributor to the CNS manifestations of Rett syndrome. Upon completion of this activity, participants should be better able to: Apply diagnostic criteria to provide a timely diagnosis of Rett syndrome in infants demonstrating subtle signs and symptoms; Implement consensus recommendations on the age-specific management of patients with Rett syndrome; and Evaluate the evidence surrounding the safety, efficacy, and tolerability of emerging pharmacologic treatment options to consider implementing these novel therapies when they become available.

Go online to PeerView.com/CNV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in thoracic oncology discusses the expanding role of biomarker testing as well as current and emerging options for targeted treatment of fusion-positive NSCLC. Upon completion of this activity, participants should be better able to: Describe the role of gene fusions, such as ALK, ROS1, NTRK, and RET, in the oncogenesis of NSCLC and the importance of detecting them in practice to inform treatment decisions; Implement best practices for biomarker testing in NSCLC, including next generation sequencing and appropriate assays for detecting gene fusions, to identify patients with gene fusions who might benefit from targeted therapy; Apply the latest evidence on targeted therapies for gene fusions to inform treatment decisions for patients with gene fusion–positive NSCLC; and Incorporate targeted therapies into individualized treatment plans for patients wit

Go online to PeerView.com/GZM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in overactive bladder discusses strategies and criteria for OAB screening and diagnosis, as well as current and emerging treatment options. A patient interview highlights the burden of disease and a 3D video illustrates the mechanisms of action of various treatments. Upon completion of this activity, participants should be better able to: Develop a strategy to implement OAB screening into clinical practice; Employ recommended diagnostic criteria to differentiate OAB from other urinary conditions with shared symptomology; and Implement individually appropriate OAB treatment plans that minimize risks related to cardiovascular health, dementia, and polypharmacy concerns.

Go online to PeerView.com/QER860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The current standards of care for managing food allergies require strict avoidance measures and prompt treatment of allergic reactions with emergency medications. However, oral immunotherapies and biologic agents are currently in development for the treatment of IgE-mediated food allergies, replacing the need for oral food challenges. Our expert faculty will share strategies for optimal clinical decision-making for patients with food allergy that is based on the latest evidence, best practice recommendations, and effective multidisciplinary collaboration. Upon completion of this activity, participants should be better able to: Describe the pathophysiology of IgE-mediated food allergy and how these insights into underlying mechanisms can translate to the use of biomarkers to allow more personalized treatment for patients; Apply strategies to differentially diagnose patients with

Go online to PeerView.com/ZXX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Prurigo nodularis (PN) causes intensely itchy, painful bumps leading to scratching, bleeding, and thickening of the nodules, with negative effects on sleep, mental health, activities of daily living, social interaction, and quality of life. There are no approved treatments for PN, but several agents in late-stage clinical trials offer hope to patients with this burdensome disease. At a recent live PeerView MasterClass & Practicum, a panel of PN experts offered evidence-based, practical guidance on current diagnostic and treatment strategies and the latest clinical data regarding novel therapies. The discussion was enhanced by a 3D animation depicting PN pathophysiology and patient videos providing perspectives on the burdens of disease and treatment experience. Upon completion of this activity, participants should be better able to: Recognize how the signs and symptoms of pr

Go online to PeerView.com/HTX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Non-cystic fibrosis bronchiectasis is a long-term respiratory condition with a significant impact on quality of life, morbidity, mortality, and use of healthcare resources. The disease manifests as chronic airway inflammation, impaired mucociliary clearance, and structural lung damage leading to recurrent infections, persistent cough, sputum production, and exacerbations. The prevalence of bronchiectasis has been on the rise. Evolving insights into the pathophysiology of bronchiectasis have led to the development of novel and emerging agents to address the underlying inflammation, with the potential of changing the treatment landscape. In this animated activity, you will learn how to optimize clinical decision-making for patients with non-cystic fibrosis bronchiectasis that is based on the latest evidence, best practice recommendations, and effective interdisciplinary collaborat

Go online to PeerView.com/QYV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Asthma is a common, chronic, and heterogeneous disease that can result in poor quality of life and severe, life-threatening exacerbations despite standard controller therapy. Type 2 inflammation, mediated by cytokines such as IL-4, IL-5, and IL-13, occurs in about 50% of patients with asthma and has emerged as a unifying feature of classically defined allergic diseases and a range of other inflammatory diseases. In this activity, an expert explains the advances in understanding of the pathogenesis of asthma and the targeted treatments that have been developed as a result. You will hear expert insights into the use of available and emerging biologic therapies, including how to identify children and adults who may be eligible for these therapies. Upon completion of this activity, participants should be better able to: Identify patients who would likely benefit from targeted therap

Go online to PeerView.com/WVA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in dermatology discusses team-based care and novel therapies in the treatment of pediatric patients with moderate to severe atopic dermatitis. Upon completion of this activity, participants should be better able to: Describe age-related and race-related differences in the phenotypic expression of atopic dermatitis (AD); Employ evidence-based strategies to determine disease impact and guide treatment decisions in pediatric patients with AD; Discuss the rationale for targeting type 2 cytokines as a therapeutic approach in AD; Assess clinical data on new and emerging treatment options for pediatric patients with moderate to severe AD; and Employ a team-based and patient-centered management approach to children and adolescents with atopic dermatitis to prevent flare-ups, identify comorbidities, maximize health-related quality of life, and recognize treatm

Go online to PeerView.com/JWM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in the management of patients with hormone receptor–positive breast cancer discuss the latest advances with TROP2-targeting antibody–drug conjugates (ADCs). Produced in collaboration with Living Beyond Breast Cancer and METAvivor, this program features a patient explaining her journey from diagnosis to participation in an important clinical trial, and faculty providing practical guidance for using TROP2-targeting ADCs in the individualized care of patients with breast cancer. Upon completion of this activity, participants should be better able to: Summarize the rationale, mechanism of action, and expanding clinical role of TROP2-targeting therapies in breast cancer; Integrate the latest safety and efficacy evidence on TROP2-targeting agents in the treatment of different subtypes of breast cancer, including TNBC and HR+ breast cancer; Develop individuali

Go online to PeerView.com/MNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live webcast, two experts in NTM-LD who represent pulmonology and infectious disease will offer their perspectives to help you achieve greater insight into the recognition and diagnosis of NTM-LD. You will hear the most up-to-date evidence on the management of NTM-LD, including both pharmacologic and nonpharmacologic approaches, and you will receive strategies for handling challenges that arise during treatment. Upon completion of this activity, participants should be better able to: Employ updated ATS/IDSA guidelines to diagnose and manage NTM-LD promptly; Develop individualized treatment regimens encompassing pharmacologic and nonpharmacologic approaches for patients with NTM-LD according to guideline recommendations and patient factors/goals; and Apply team-based strategies to manage medication adverse events, improve treatment adherence, d

Go online to PeerView.com/AHC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in HIV prevention discuss how telehealth has transformed access to quality PrEP services in the era of COVID-19 and resources available to help clients in maximizing the full benefits of innovative HIV prevention measures. Upon completion of this activity, participants should be better able to: Discuss how telehealth has transformed access to quality HIV prevention and care services in the era of COVID-19; Outline the telehealth technical resources available to maximize the full benefits of innovative HIV prevention measures; and Identify opportunities and strategies to leverage existing resources and infrastructure development to support the extension/utilization of telehealth services for PrEP by the healthcare team.

Go online to PeerView.com/WKU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hypertrophic cardiomyopathy (HCM) is estimated to affect as many as 15 to 20 million people worldwide. However, it remains frequently undetected, because its symptoms are often nonspecific or mistaken for more common conditions. In this discussion-based activity, leading experts on HCM get to the heart of the matter, diagnosis and treatment, as they review guideline recommendations on imaging for diagnosis and examine current and novel treatment options, including small-molecule myosin inhibitors, as a means to improve patient outcomes and quality of life. Upon completion of this activity, participants should be better able to: Differentially diagnose patients suspected of having HCM consistent with current guidance using appropriate cardiac imaging techniques; Apply the latest recommendations and current guidance for diagnosing, evaluating, and managing patients with HCM in a c

Go online to PeerView.com/DBP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on obesity management discusses current evidence for anti-obesity medications and shares evidence-based strategies to individualize weight-loss regimens and improve health outcomes. Upon completion of this activity, participants should be better able to: Recognize the role of weight-loss pharmacotherapy for reducing risks and addressing obesity as a chronic disease, including effects on appetite regulation, metabolic adaptation, and preventing/managing obesity-related complications, adjunct to lifestyle modification; Assess current guidance and available long-term efficacy and safety data for current and emerging weight-loss pharmacotherapies in people with or at risk for obesity; and Incorporate weight-loss pharmacotherapy, as appropriate, into individualized, evidence-based treatment plans for long-term obesity management.

Go online to PeerView.com/TFR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Who holds the key that can unlock the door to vision-saving treatments for patients with diabetic retinopathy (DR) and diabetic macular edema (DME)? The answer is primary diabetes care professionals: Timely screening and referral to eye care professionals can make a real difference between good vision and blindness for patients with DR/DME. The diagnosis and treatment of DR/DME has advanced greatly in the last decade. What can endocrinologists, diabetologists, and primary diabetes care professionals tell their patients to expect when they meet with a retina specialist? In this activity, based on a recent PeerView Live event, leading experts take a well-rounded look at the screening, diagnosis, and referral for treatment of individuals with DR/DME, including a practical review of the evidence for current and emerging treatment options. The experts discuss patient cases with varyi

Go online to PeerView.com/RBU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses the recognition of axial spondyloarthritis (axSpA) and integrating the latest evidence into the management of patients with axSpA. Upon completion of this activity, participants should be better able to: Identify the specific domains of axial spondyloarthritis (axSpA) and their relationship to quality of life; Apply classification criteria and diagnostic tests into clinical practice to identify axSpA in patients with inflammatory back pain; Assess efficacy and safety data related to novel biologic options for axSpA, recognizing the potential clinical impact on the management of patients who do not respond well to traditional pharmacologic therapies; Employ treatment plans for individual patients with axSpA in accordance with current evidence, expert recommendations, and patient needs and preferences; and Collaborate with rheumatologists to p

Go online to PeerView.com/REK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. For individuals with multiple sclerosis (MS), “invisible symptoms” that include cognitive changes and fatigue exacerbate the burden of disease. Emerging evidence indicates that in addition to providing high efficacy, safety, tolerability, and patient convenience, sphingosine 1-phosphate receptor (S1PR) modulators may yield important benefits related to loss of cortical gray matter and whole brain volume, addressing cognition as well as multiple other aspects of MS. At a recent live event, our expert faculty reviewed the mechanism of action of S1PR modulators and their important role in MS care, with a focus on the clinically relevant distinctions among members of this class—from first-generation fingolimod to the more recently introduced siponimod, ozanimod, and ponesimod. The faculty discussed the role of agent-specific characteristics such as relative selectivity and off-targe

Go online to PeerView.com/REA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Listen to our expert faculty as they discuss new and emerging therapies for AA and AD, with a focus on mechanisms of action, efficacy and safety profiles, nuances of administration and use, and risk:benefit profile. You will also hear about novel therapies in late-stage development for the treatment of moderate to severe AD and AA. The Late Night inExchange format is designed to meet the educational needs of clinicians with practice-relevant education presented in an engaging multi-faculty discussion format that brings knowledge to life. Through this format, learners will be better able to see how conceptual knowledge of AA and AD translates to actual practice. Upon completion of this activity, participants should be better able to: Appropriately assess the severity of atopic dermatitis (AD) and alopecia areata (AA) to determine the best treatment strategy in individual patients

Go online to PeerView.com/XJG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Systemic lupus erythematosus (SLE) is an autoimmune disease associated with substantial morbidity and mortality, especially in women. The disease causes progressive damage to multiple organ systems and reduces quality of life. Improving your understanding of SLE heterogeneity at the clinical and mechanistic level can drive significant improvements across the care spectrum. In this expert-driven activity, you will hear the latest clinical evidence presented during the European Alliance of Associations for Rheumatology (EULAR) 2022 Congress in Copenhagen, Denmark, with regard to the current treatment options for SLE and the potential for TYK2 inhibitors to change SLE management. Upon completion of this activity, participants should be better able to: Recognize the burden of SLE and the impact of delayed or suboptimal treatment on patient outcomes; Describe the mechanistic rational

Go online to PeerView.com/DGJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to date on recent evidence on acute lymphoblastic leukemia (ALL) emerging from major scientific congresses? In this activity, an ALL specialist explores recent evidence presented at the 2022 American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) annual meetings on developments in various treatment modalities for ALL. Watch this video to hear about the latest evidence and practical applications in asparaginase use in chemotherapy protocols, including important dosing and safety data on recombinant Erwinia; get updated on longer-term outcomes with CAR-T therapy in adult and pediatric patients and hear practical considerations when using CAR-T options; and learn about emerging chemo-sparing TKI plus bispecific combinations in Ph-positive ALL. Upon completion of this activity, participants should be better able to: Summarize new evidence on

Go online to PeerView.com/EWZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Solid organ transplant recipients may be at increased risk for COVID-19 because they are immunosuppressed and less likely to mount effective immune responses to vaccination. In this educational symposium based on a live event, a panel of expert faculty address the identification of transplant patients who would likely derive benefit from anti-SARS-CoV-2 monoclonal antibodies (mAbs) and strategies that can be used to overcome barriers to COVID-19 pre-exposure prophylaxis access. In addition, they provide guidance on mAb qualities and clinical profiles and shared decision-making strategies to customize mAb pre-exposure prophylaxis at the point of care for transplant recipients needing protection against COVID-19. After participating in this activity, the learner will demonstrate the ability to: Identify post-transplant patients who would likely derive benefit from pre-exposure pro